Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics IncfiledCriticalSage Therapeutics Inc
Publication of AR112813A1publicationCriticalpatent/AR112813A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Métodos para tratar un trastorno del sueño -por ejemplo, insomnio- en un sujeto, que comprende administrar al sujeto una cantidad efectiva de un compuesto que tiene la fórmula (1) o una sal farmacéuticamente aceptable del mismo.Methods of treating a sleep disorder - eg, insomnia - in a subject, comprising administering to the subject an effective amount of a compound having the formula (1) or a pharmaceutically acceptable salt thereof.
ARP180102626A2017-09-142018-09-14
A C21-N-PIRAZOLYL 19-NOR C3,3-DISUSTITUTED STEROID, AND METHODS OF USE OF THE SAME
AR112813A1
(en)
Compounds derived from pyridinone, bromodomain inhibitors; pharmaceutical composition comprising them; and its use in the treatment of cancer diseases. (divisional application 201600925)
USE OF THE 3,5-DIHIDROXI-4-ISOPROPIL-TRANS-ESTILBENE COMPOUND FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION, SUCH COMPOUND AND PHARMACEUTICAL COMPOSITION THAT INCLUDES IT